J&J Says Tremfya Meets Primary And Major Secondary Endpoints In Axial PsA Study

By Reuters News

Sept 25 (Reuters) - Johnson & Johnson JNJ.N:

  • JOHNSON & JOHNSON ANNOUNCES TREMFYA® (GUSELKUMAB) IS THE FIRST AND ONLY IL-23 INHIBITOR TO SHOW SIGNIFICANT IMPROVEMENT IN SPINAL PAIN AND STIFFNESS IN LANDMARK AXIAL PSORIATIC ARTHRITIS (PSA) STUDY

  • J&J - TREMFYA MEETS PRIMARY AND MAJOR SECONDARY ENDPOINTS IN AXIAL PSA STUDY

  • J&J - TREMFYA MEETS MAJOR SECONDARY ENDPOINTS FOR AXIAL SYMPTOMS AND MRI INFLAMMATION REDUCTION

  • J&J - STAR STUDY SHOWS TREMFYA SAFETY PROFILE CONSISTENT WITH PSA; NO NEW SAFETY SIGNALS

  • J&J - TREMFYA MEETS PRIMARY ENDPOINT FOR BASDAI SCORE IMPROVEMENT AT WEEK 24

Further company coverage: JNJ.N

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.